Precision, bias, and clinical utility of the sheiner-tozer equation to guide phenytoin dosing in critically ill adults

Journal of Clinical Pharmacology

Volumn 53, Issue 4, 2013, Pages 451-455

  Bolt, Jennifer ^a   Gorman, Sean K ^a,b  

^a Interior Health Authority   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Critical illness; Pharmacokinetics; Phenytoin; Predictive equations; Therapeutic drug monitoring

Indexed keywords

PHENYTOIN;

ACCURACY; ARTICLE; CRITICAL ILLNESS; CRITICALLY ILL PATIENT; DOSE CALCULATION; DRUG MONITORING; HUMAN; MATHEMATICAL MODEL; SEIZURE; SHEINER TOZER EQUATION; TRAUMATIC BRAIN INJURY;

ADULT; ALGORITHMS; ANTICONVULSANTS; CRITICAL ILLNESS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; PHENYTOIN;

EID: 84877850101     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.27     Document Type: Article

References (17)

1. Bratton SL, Chestnut RM, Ghajar J, et al. Antiseizure prophylaxis. J Neurotrauma. 2007;24(Suppl 1):S83-S86.
2. Meierkord H, Boon P, Engelson B, et al. EFNS guideline on the management of status epilepticus. Eur J Neuro. 2006;13:445-450.
3. Patsalos PN, Berry DJ, Bourgeois BF, et al. Antiepileptic drugs-best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia. 2008;49:1239-1276.
4. Peterson GM, Khoo BH, von Witt RJ. Clinical response in epilepsy in relation to total and free serum levels of phenytoin. Ther Drug Monit. 1991;13:415-419.
5. von Winckelmann SL, Spriet I, Willems L. Therapeutic drug monitoring of phenytoin in critically ill patients. Pharmacotherapy. 2008;28:1391-1400.
6. Lenn NJ, Robertson M. Clinical utility of unbound antiepileptic drug blood levels in the management of epilepsy. Neurology. 1992;42: 988-990.
7. Winter ME, Tozer TN. Phenytoin. In: Burton ME, Shaw LM, Schentag JJ, Evans WE, eds. Applied Pharmacokinetics & Pharmacodynamics. Principles of Therapeutic Drug Monitoring. 4th ed. Baltimore MD: Lippincott Williams & Wilkins; 2006: 463-490.
8. Ibarra M, Vazquez M, Fagiolino P, Mutilva F, Canale A. Total, unbound plasma and salivary phenytoin levels in critically ill patients. J Epilepsy Clin Neurophysiol. 2010;16:69-73.
9. Sheiner LB, Tozer TN. Clinical pharmacokinetics: the use of plasma concentrations of drugs. In: Melmon KL, Morelli HF, eds. Clinical Pharmacology: Basic Principles in Therapeutics. New York: Macmillan; 1978: 71-109.
10. Wolf GK, McClain CD, Zurakowski D, Dodson B, McManus M. Total phenytoin concentrations do not accurately predict free phenytoin concentrations in critically ill children. Pediatr Crit Care Med. 2006;7:434-439.
11. Sheiner LB, Beal SL. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm. 1981;9:503-512.
12. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet. 1986;1:307-310.
13. Mauro LS, Mauro VF, Bachmann KA, Higgins JT. Accuracy of two equations in determining normalized phenytoin concentrations. DICP. 1989;23:64-68.
14. Zielmann S, Mielck F, Kahl R, et al. A rational basis for the measurement of free phenytoin concentration in critically ill trauma patients. Ther Drug Monit. 1994;16:139-144.
15. Mlynarek ME, Peterson EL, Zarowitz BJ. Predicting unbound phenytoin concentrations in the critically ill neurosurgical patient. Ann Pharmacother. 1996;30:219-223.
16. Shohrati M, Mojtahedzadeh M, Reza Rouini MR, et al. Correlation of free fraction of phenytoin and plasma albumin level in head trauma patients. DARU J Pharm Sci. 2002;10:1-5.
17. Rimmer EM, Buss DC, Routledge PA, Richens A. Should we routinely measure free plasma phenytoin concentration? Br J Clin Pharmac. 1984;17:99-102.